Leishmaniasis: Public health aspects and control

Clinics in Dermatology

Volumn 14, Issue 5, 1996, Pages 417-423

  Desjeux, Philippe ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEISHMANIAL AGENT; MEGLUMINE ANTIMONATE; PAROMOMYCIN; PENTAMIDINE; STIBOGLUCONATE SODIUM;

GEOGRAPHIC DISTRIBUTION; HEALTH CARE POLICY; HEALTH EDUCATION; HUMAN; INFECTION CONTROL; INFECTION RISK; LEISHMANIASIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; SKIN LEISHMANIASIS; VECTOR CONTROL; VISCERAL LEISHMANIASIS;

EID: 0030249268     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0738-081X(96)00057-0     Document Type: Article

References (21)

1. 1. Control of the leishmaniases. Report of a WHO Expert Committee. Technical Report Series, 793, Geneva: WHO, 1990.
2. 2. Ashford RW, Desjeux P, De Raadt P. Estimation of population at risk of infection with leishmaniasis. Parasitol Today 1991;8:104-5.
3. 3. Desjeux P. Information on the epidemiology and control of the leishmaniases by country or territory. WHO/ LEISH/91.30. Geneva: CTD/TRY, WHO, 1991.
4. 4. Walsh JA, Warren KS. N Engl J Med 1979;301:967-74.
5. 5. Badaro R, Jones TC, Carvalho EM. New perspective on a sub-clinical form of leishmaniasis. J Infect Dis 1986;154: 1003-11.
6. 6. Seaman J, et al. Visceral leishmaniasis in southern Sudan: Status of healthy villagers in epidemic conditions. Ann Trop Med Parasitol 1992;86:481-6.
7. 7. Report on the Consultative Meeting on Leishmania/HIV co-infection, Rome, 6-7 September, 1994 (WHO/LEISH/ 95.35).
8. 8. WHO guidelines for leishmaniasis control at regional and subregional levels (WHO/LEISH/88-25). Geneva: PDP, WHO, 1988.
9. 9. International Development Research Centre (IDRC). Research on control strategies for the leishmaniases: Proceedings of an international workshop, Ottawa, Canada, 1-4 June 1987. Leishmaniases: A global problem. Walton BC. Manuscript Report 184e, 1-5.
10. 10. Guerra H. Role of national data centres and obligatory reporting in control programs. In Ibid.
11. 11. Copeland HW, Arana BA, Navin TR, et al. Comparison of active and passive case detection of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg 1990;43:257-9.
12. 12. The "killing disease" soars in South Sudan. TDR News 37. Geneva: TDR Communication, WHO, November 1991:1.
13. 13. Zijlstra EE. Kala-azar in the Sudan, epidemiological and clinical studies. Thesis. University of Amsterdam. 1995: 245 p.
14. 14. Singla N, Singh GS, Sundar S, et al. Evaluation of the direct agglutination test as an immunodiagnostic tool for kala-azar in India. Trans R Soc Trop Med Hyg 1993;87: 276-8.
15. 15. Chowdhury MS, el Harrith A, al Massum A, et al. Prevalence of agglutinating anti-Leishmania antibodies in two multi-thousand Bengali communities. Parasitol Res 1993; 79:444-50.
16. 16. Olliaro PL, Bryceson ADM. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today 1993;9:323-8.
17. 17. Asilian A, Jalayer T, Whitworth JAG, et al. A randomized placebo-controlled trial of a two-week regiment of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 1995;53:162-6.
18. 18. Ben Salah A, Zakraoui H, Zaatour A, et al. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 1995;53:162-6.
19. 19. International Development Research Centre (IDRC). Research on control strategies for the leishmaniases: Proceedings of an international workshop, Ottawa, Canada, 1-4 June 1987. Badaro R. The identification of risks factors associated with the transmission of New World visceral leishmaniasis. Manuscript Report 184e, pp. 261-3.
20. 20. Harrison LH. Reciprocal relationships between under nutrition and the parasitic disease visceral leishmaniasis. Rev Infect Dis 1986;8:447-53.
21. 21. Tropical Disease Research, Twelfth Programme Report, UNDP/World Bank/WHO special Programme for Research and Training in Tropical Diseases (TDR). Geneva: WHO, 1995:135-46.